In this sense, PPARγ ligands of the antidiabetic thiazolidinediones group are being used as a treatment of obesity comorbidities such as dyslipidaemia and type 2 diabetes (Cariou et al., 2012), but questions have arisen in this regard (Gross et al., 2017) as the development of these pharmacological activators of PPARγ requires a complete knowledge of the PPARγ-regulated control of glucose and lipid metabolism (Cataldi et al., 2021). This evidence concerns the gene PPARG and obesity disorder.